

information whose disclosure is restricted by statute.

Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

FOR FURTHER INFORMATION CONTACT: Patrick Yellin, Monitoring, Assistance, and Media Programs Division, Office of Compliance, Mail Code 2227A, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564–2970; fax number: (202) 564–0050; email address: yellin.patrick@epa.gov.

SUPPLEMENTARY INFORMATION: Supporting documents, which explain in detail the information that EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at www.regulations.gov, or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202–566–1744. For additional information about EPA’s public docket, visit: <http://www.epa.gov/dockets>.

Abstract: Owners and operators of affected facilities are required to comply with reporting and recordkeeping requirements for the General Provisions (40 CFR part 63, subpart A), as well as the applicable standards at 40 CFR part 63, subpart W. This includes submitting initial notifications, performance tests and periodic reports and results, and maintaining records of the occurrence

and duration of any startup, shutdown, or malfunction in the operation of an affected facility, or any period during which the monitoring system is inoperative. These reports are used by EPA to determine compliance with these standards.

Form Numbers: None.
Respondents/affected entities: Epoxy resin and non-nylon polyamide resin production facilities.

Respondent’s obligation to respond: Mandatory (40 CFR part 63, subpart W).

Estimated number of respondents: 7 (total).

Frequency of response: Initially, quarterly, and semiannually.

Total estimated burden: 3,940 hours (per year). Burden is defined at 5 CFR 1320.3(b).

Total estimated cost: \$476,000 (per year), which includes \$14,000 in annualized capital/startup and/or operation & maintenance costs.

Changes in the Estimates: There is no increase in burden from the most recently approved ICR as currently identified in the OMB Inventory of Approved Burdens. This is due to two considerations: (1) The regulations have not changed over the past three years, and they are not anticipated to change over the next three years; (2) the growth rate for this industry is either very low or non-existent, so there is no significant change in the overall burden. However, there is a slight increase in costs. The operation and maintenance (O&M) costs have been updated from 1998 dollars to 2019 dollars using the CEPCI CE Index.

Courtney Kerwin,
Director, Regulatory Support Division.
[FR Doc. 2021–03793 Filed 2–23–21; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL TRADE COMMISSION

Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice made the grants. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

EARLY TERMINATIONS GRANTED

[01/01/2021 12:00:00 a.m., 01/31/2021 12:00:00 a.m.]

01/04/2021

20210673	G	TransDigm Group Incorporated; AI Convoy (Cayman) Limited; TransDigm Group Incorporated.
20210692	G	Marlin Equity V, L.P.; Luminare Capital Partners, LP; Marlin Equity V, L.P.
20210695	G	Partners Group Access 77 PF LP; New Mountain Partners IV, L.P.; Partners Group Access 77 PF LP.
20210697	G	Aurora Innovation, Inc; Uber Technologies, Inc; Aurora Innovation, Inc.
20210698	G	Uber Technologies, Inc.; Aurora Innovation, Inc; Uber Technologies, Inc.
20210699	G	Howard W. Lutnick; View, Inc.; Howard W. Lutnick.
20210701	G	Humana Inc.; Rajendra K. Bansal; Humana Inc.
20210702	G	Star Peak Energy Transition Corp.; Stem, Inc.; Star Peak Energy Transition Corp.
20210703	G	Columna Datamars S.a.r.l.; Datamars Investments S.a.r.l.; Columna Datamars S.a.r.l.
20210708	G	Warburg Pincus Global Growth, L.P.; Tony Olson; Warburg Pincus Global Growth, L.P.
20210709	G	L Catterton IX, L.P.; Truck Hero Holdings, Inc.; L Catterton IX, L.P.
20210713	G	SK Holdings Co., Ltd.; Roivant Sciences Ltd.; SK Holdings Co., Ltd.
20210718	G	AbbVie Inc.; Eiger BioPharmaceuticals, Inc.; AbbVie Inc.

01/11/2021

20210700	G	Huntsman Corporation; Audax Private Equity Fund IV AIV, L.P.; Huntsman Corporation.
20210712	G	Andrea Pignataro; Flexpoint Fund III, L.P; Andrea Pignataro.
20210719	G	OCM RGCY PT, L.P. ; Drake Kennedy; OCM RGCY PT, L.P.

EARLY TERMINATIONS GRANTED—Continued

[01/01/2021 12:00:00 a.m., 01/31/2021 12:00:00 a.m.]

20210723	G	Leidos Holdings, Inc; Sumeet Singh; Leidos Holdings, Inc.
20210724	G	Roger S. Penske; Roger S. Penske; Roger S. Penske.
20210732	G	Rhone Partners V L.P.; Gruppo Illy S.p.A; Rhone Partners V L.P.
20210733	G	Fiserv, Inc.; Ondot Systems, Inc.; Fiserv, Inc.
20210734	G	Primoris Services Corporation; Future Infrastructure Holdings, LLC; Primoris Services Corporation.

01/12/2021

20210728	G	The Veritas Capital Fund VII, L.P.; Northrop Grumman Corporation; The Veritas Capital Fund VII, L.P.
20210729	G	The Veritas Capital Fund VII, L.P.; The Veritas Capital Fund V, L.P.; The Veritas Capital Fund VII, L.P.
20210740	G	Mercuria Energy Group Holding Ltd.; HC2 Holdings, Inc; Mercuria Energy Group Holding Ltd.
20210741	G	CCP III AIV V, L.P. ; New Speedcast Parent; CCP III AIV V, L.P.
20210742	G	Magna International Inc.; Dr. Geeta Gupta and Henrik Fisker; Magna International Inc.
20210746	G	Oaktree Opportunities Fund XI, L.P.; S1 Blocker Buyer, Inc.; Oaktree Opportunities Fund XI, L.P.
20210747	G	The Huron Fund V L.P.; Doug DeClusin; The Huron Fund V L.P.
20210748	G	Partners Group Access 75 PF LP; New Harbor Wedgewood; Partners Group Access 75 PF LP.

01/13/2021

20210737	G	Oshkosh Corporation; James F. Miller; Oshkosh Corporation.
20210749	G	PTC Inc.; JMI Equity Fund VIII-A, L.P.; PTC Inc.
20210750	G	Total SE; Dong Kwan Kim; Total SE.
20210752	G	Alexander Karp; Palantir Technologies Inc.; Alexander Karp.
20210753	G	Stephen Cohen; Palantir Technologies Inc.; Stephen Cohen.
20210756	G	H.I.G. Middle Market LBO Fund III, L.P.; Incline Equity Partners IV, L.P.; H.I.G. Middle Market LBO Fund III, L.P.
20210757	G	Paysafe Limited; Paysafe Group Holdings Limited; Paysafe Limited.
20210758	G	William P. Foley, II; Paysafe Group Holdings Limited; William P. Foley, II.
20210759	G	Cannae Holdings, Inc.; Paysafe Group Holdings Limited; Cannae Holdings, Inc.
20210762	G	Cronos TopCo LP; New Mountain Partners V, L.P.; Cronos TopCo LP.
20210768	G	Murphy USA Inc.; Dean C. Durling; Murphy USA Inc.
20210777	G	Fortress Credit Opportunities Fund V (G) L.P.; Fidentia Fortuna Holdings, Ltd.; Fortress Credit Opportunities Fund V (G) L.P.
20210778	G	Vesper Healthcare Acquisition Corp.; LCP Edge Holdco, LLC; Vesper Healthcare Acquisition Corp.
20210779	G	United States Steel Corporation; Big River Steel Holdings LLC; United States Steel Corporation.
20210782	G	Jonathan Oringer; Shutterstock, Inc.; Jonathan Oringer.

01/15/2021

20210173	S	Albertsons Companies, Inc.; KB US Holdings, Inc.; Albertsons Companies, Inc.
20210380	G	Allied Universal Topco LLC; Frank and Kathleen Argenbright; Allied Universal Topco LLC.
20210760	G	ContourGlobal L.P.; Harbert Power Fund V, LLC; ContourGlobal L.P.
20210775	G	Amphenol Corporation; MTS Systems Corporation ; Amphenol Corporation.
20210783	G	KPS Special Situations Fund IV, LP; Ernest W. Giddens; KPS Special Situations Fund IV, LP.
20210787	G	TCV X, L.P.; Newsela Inc.; TCV X, L.P.
20210790	G	Kemper Corporation; American Access Group, LLC; Kemper Corporation.
20210791	G	Silver Spike Acquisition Corp.; WM Holding Company, LLC; Silver Spike Acquisition Corp.
20210794	G	Charlesbank Equity Fund IX, Limited Partnership; SPC Partners V, L.P.; Charlesbank Equity Fund IX, Limited Partnership.
20210795	G	LPL Financial Holdings Inc.; Macquarie Group Limited; LPL Financial Holdings Inc.
20210796	G	American Securities Partners VIII, L.P.; Beacon Roofing Supply, Inc.; American Securities Partners VIII, L.P.
20210797	G	Koninklijke Philips N.V.; Francisco Partners Agility, L. P.; Koninklijke Philips N.V.
20210798	G	The Resolute Fund V, L.P.; Madison Dearborn Capital Partners VII-A, L.P.; The Resolute Fund V, L.P.
20210799	G	Stillfront Group AB; Super Free Games, Inc.; Stillfront Group AB.
20210800	G	United Therapeutics Corporation; Y-mAbs Therapeutics, Inc.; United Therapeutics Corporation.
20210801	G	Temasek Holdings (Private) Limited; Kazuhide Nakano; Temasek Holdings (Private) Limited.
20210803	G	Macquarie Group Limited; Waddell & Reed Financial, Inc.; Macquarie Group Limited.
20210804	G	TC Energy Corporation; TC PipeLines, LP; TC Energy Corporation.
20210805	G	The Veritas Capital Fund VII, L.P.; HMS Holdings Corp.; The Veritas Capital Fund VII, L.P.
20210806	G	Matthew Rabinowitz; Natera, Inc.; Matthew Rabinowitz.
20210808	G	Cerner Corporation; Bain Capital Europe Fund V, SCSp; Cerner Corporation.
20210843	G	George Archos; Majesta Minerals, Inc.; George Archos.

FOR FURTHER INFORMATION CONTACT: Theresa Kingsberry (202–326–3100), Program Support Specialist, Federal Trade Commission Premierger Notification Office, Bureau of Competition, Room CC–5301, Washington, DC 20024.

By direction of the Commission.

Joel Christie,
Acting Secretary.

[FR Doc. 2021–03751 Filed 2–23–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE21–002: Research Grants to Develop or Identify Effective Strategies to Prevent Overdose Involving Illicit Stimulants and Polysubstance Use Involving Stimulants.

Dates: June 15–16, 2021.

Times: 8:30 a.m.–5:00 p.m., EDT.

Place: Videoconference.

Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT: Mikel Walters, Ph.D., Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, MWalters@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been

delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–03744 Filed 2–23–21; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[60Day–20–0051; Docket No. ATSDR–2020–0005]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled “Assessment of Chemical Exposures (ACE) Investigations.” The purpose of ACE Investigations is to focus on performing rapid epidemiological assessments to assist state, regional, local, or tribal health departments (the requesting agencies) to respond to or prepare for acute environmental incidents.

DATES: ATSDR must receive written comments on or before April 26, 2021.

ADDRESSES: You may submit comments, identified by Docket No. ATSDR–2020–0005 by any of the following methods:

- *Federal eRulemaking Portal:* [Regulations.gov](https://www.regulations.gov). Follow the instructions for submitting comments.

- *Mail:* Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329.

Instructions: All submissions received must include the agency name and

Docket Number. ATSDR will post, without change, all relevant comments to [Regulations.gov](https://www.regulations.gov).

Please note: Submit all comments through the Federal eRulemaking portal ([regulations.gov](https://www.regulations.gov)) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329; phone: 404–639–7118; Email: omb@cdc.gov.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

3. Enhance the quality, utility, and clarity of the information to be collected; and

4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

5. Assess information collection costs.

Proposed Project

Assessment of Chemical Exposures (ACE) Investigations (OMB Control No. 0923–0051)—Reinstatement with